Human Immunodeficiency Virus (HIV) Infections Completed Phase 2 Trials for INCB-9471 (DB12960)

Also known as: Human Immunodeficiency Virus-Infection / HIV-Infections / Human Immunodeficiency Virus Infections / HIV Infections / Human Immunodeficiency Virus (HIV) Infection / Human Immunodeficiency Virus Infection (HIV) / HIV Infection / Human Immunodeficiency Virus Infection / HIV-Infection / Infection, Human Immunodeficiency Virus / Human Immunodeficiency Viruses / Virus, Human Immunodeficiency / HIV - Human Immunodeficiency Virus / Human Immunodeficiency Virus / Human Immunodeficiency Virus (HIV) / HIV (Human Immunodeficiency Virus) / Human Immunodeficiency Virus; HIV / HIV (Human Immuno-Deficiency Virus) / HIV / HIV Disease / [X]Human immunodeficiency virus disease (disorder) / Human immunodeficiency virus [HIV] disease / [X]Unspecified human immunodeficiency virus [HIV] disease (disorder) / (AIDS) or (HIV infection) / HTLV-III/LAV infection -RETIRED- / HIV infection NOS / Human immunodeficiency virus syndrome / Human immunodeficiency virus infection, unspecified / Human immunodeficiency virus infection (disorder) / Human immunodeficiency virus (organism) / T-lymphotropic virus (organism)

IndicationStatusPhase
DBCOND0035016 (Human Immunodeficiency Virus (HIV) Infections)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00393120Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected PatientsTreatment